Abstract | BACKGROUND: METHODS: For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of n = 407 individuals. The diagnostic groups comprised Alzheimer's disease (n = 74), vascular dementia (n = 28), other important differential diagnoses (n = 221), and healthy controls (n = 84). Main results were validated in an independent cohort with patients with Alzheimer's disease (n = 19), mild cognitive impairment (n = 27), and healthy individuals (n = 28). RESULTS: Plasma Lipocalin-2 was significantly lower in Alzheimer's disease compared to healthy controls (p < 0.001) and all other groups (p < 0.01) except for mixed dementia (vascular and Alzheimer's pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer's disease and healthy controls were 0.783 (95%CI: 0.712-0.855) in the study cohort and 0.766 (95%CI: 0.627-0.905) in the validation cohort. The area under the curve for Alzheimer's disease versus vascular dementia was 0.778 (95%CI: 0.667-0.890) in the study cohort. In Alzheimer's disease patients, plasma Lipocalin2 did not show significant correlation with cerebrospinal fluid biomarkers of neurodegeneration and AD-related pathology (total-tau, phosphorylated tau protein, and beta-amyloid 1-42), cognitive status (Mini Mental Status Examination scores), APOE genotype, or presence of white matter hyperintensities. Interestingly, Lipocalin 2 was lower in patients with rapid disease course compared to patients with non-rapidly progressive Alzheimer's disease (p = 0.013). CONCLUSIONS:
|
Authors | Peter Hermann, Anna Villar-Piqué, Matthias Schmitz, Christian Schmidt, Daniela Varges, Stefan Goebel, Timothy Bunck, Hanna Lindemann, Carla Bogner, Isabel Santana, Inês Baldeiras, Joachim Riggert, Inga Zerr, Franc Llorens |
Journal | Alzheimer's research & therapy
(Alzheimers Res Ther)
Vol. 14
Issue 1
Pg. 9
(01 13 2022)
ISSN: 1758-9193 [Electronic] England |
PMID | 35027079
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022. The Author(s). |
Chemical References |
- Amyloid beta-Peptides
- Biomarkers
- Lipocalin-2
- tau Proteins
|
Topics |
- Alzheimer Disease
(blood, cerebrospinal fluid, diagnosis)
- Amyloid beta-Peptides
(blood, cerebrospinal fluid)
- Biomarkers
(blood, cerebrospinal fluid)
- Case-Control Studies
- Cognitive Dysfunction
(diagnosis)
- Diagnosis, Differential
- Humans
- Lipocalin-2
(blood)
- tau Proteins
|